Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Schattenberg JM, et al. Among authors: ratziu v. Liver Int. 2021 Jun;41(6):1227-1242. doi: 10.1111/liv.14825. Epub 2021 Mar 18. Liver Int. 2021. PMID: 33590598 Free PMC article. Review.
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T; LIDO Study Group; CYTOL study group. Ratziu V, et al. BMC Gastroenterol. 2006 Feb 14;6:6. doi: 10.1186/1471-230X-6-6. BMC Gastroenterol. 2006. PMID: 16503961 Free PMC article.
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Poynard T, et al. Among authors: ratziu v. BMC Gastroenterol. 2006 Nov 10;6:34. doi: 10.1186/1471-230X-6-34. BMC Gastroenterol. 2006. PMID: 17096854 Free PMC article.
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Poynard T, et al. Among authors: ratziu v. BMC Gastroenterol. 2007 Oct 15;7:40. doi: 10.1186/1471-230X-7-40. BMC Gastroenterol. 2007. PMID: 17937811 Free PMC article.
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V. Poynard T, et al. Among authors: ratziu v. Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):720-30. doi: 10.1016/j.clinre.2011.07.003. Epub 2011 Aug 17. Clin Res Hepatol Gastroenterol. 2011. PMID: 21852224
404 results